BioSymetrics Inc.

BioSymetrics Inc. is a healthcare and biomedical artificial intelligence company based in Huntington, New York, United States, that develops machine learning platforms to accelerate drug discovery and precision medicine. The organization utilizes its proprietary Augusta framework to process diverse biomedical datasets, including genomics, chemistry, medical imaging, and electronic health records, to identify novel therapeutic targets. Operating with an estimated 10 to 50 employees and backed by $5 million in Series A funding, the firm generates revenue through platform licensing and collaborative research agreements with recognizable healthcare entities like Janssen Pharmaceutica, Northwell Health, and Sema4. Following its acquisition by Renovaro BioSciences in February 2025, the enterprise continues to advance its proprietary therapeutic pipeline alongside its software services. BioSymetrics was formally founded in 2015 by Chief Executive Officer Anthony Iacovone and Chief Scientific Officer Gabriel Musso.

High-Level Overview

BioSymetrics Inc. is a phenomics-driven drug discovery company that integrates clinical and experimental data with machine learning to identify new drug targets and advance precision medicines, primarily in neurological, cardiometabolic, and rare diseases.[1][2][3][4] It serves pharmaceutical companies, healthcare systems, and research organizations—such as Janssen, Northwell Health, Sema4, and Mt. Sinai—by providing end-to-end drug discovery from clinical strategy to small molecule screening, leveraging over 77 million patient records and 1 million genomic profiles.[2][3][4] The company addressed the high failure rate of clinical trials (90% due to lack of efficacy) through AI predictions coupled with in vivo validation for faster, higher-confidence targets; its lead programs target epilepsies, including the KCC2 program identifying hits like BIOS-1073 that reverse seizure phenotypes in zebrafish models.[4] In February 2025, BioSymetrics was acquired by Renovaro BioSciences, enhancing Renovaro's AI-powered biomarker and diagnostic platform with BioSymetrics' Elion AI engine and Phenograph translational tool for oncology, epilepsy, and beyond.[1]

Origin Story

Founded in 2015 and initially based in Huntington, New York, with later operations in Cambridge, Massachusetts, Toronto, and California as a remote-first company, BioSymetrics emerged to tackle the limitations of reductionist drug discovery approaches amid complex biology.[1][2][3][4] The founders built on a vision to "translate data into discoveries" by combining clinical phenomics data with machine learning, patent-pending Contingent-AI™ for bias correction, and in vivo validation.[2][3][4] Early traction came from partnerships with leading entities like Deerfield Management (2022 collaboration on cardiology and neurology targets), Northwell Health, Janssen, and Sema4, enabling access to massive datasets and advancing programs in epilepsy and other areas.[2][3][4] This network-driven growth culminated in the February 2025 acquisition by Renovaro BioSciences, merging expertise in neurological diseases with Renovaro's oncology focus to accelerate precision drug development.[1]

Core Differentiators

• AI-Driven Phenomics Platform: Uses Elion (machine learning engine) and Phenograph (translational mapper) to integrate 77M+ patient records, 1M+ genomic profiles, and model systems for target discovery, patient stratification, and drug repurposing—outpacing traditional methods.[1][4]
• In Vivo Validation Speed: Combines AI predictions with high-content zebrafish screening (e.g., 15,000+ data points per video in KCC2 epilepsy program), identifying novel hits like BIOS-1073 in months, ensuring translational confidence.[4]
• Bias-Resistant Tech: Contingent-AI™ detects and corrects biases pre-processing, unlocking contingent features for more accurate human disease modeling.[3]
• Proven Partnerships: Collaborations with pharma giants (Janssen, Deerfield) and health systems provide diverse, real-world data, fueling a pipeline in hard-to-treat areas like epilepsies, cardiometabolic, and rare diseases.[2][3][4]

Role in the Broader Tech Landscape

BioSymetrics rides the AI-in-drug-discovery wave, addressing the 90% clinical trial failure rate by bridging phenomics (disease phenotypes) with genomics via machine learning and rapid in vivo testing—critical as precision medicine demands multimodal data integration.[1][4] Timing aligns with surging investments in AI-biotech (e.g., post-2022 Deerfield deal) and post-2025 acquisition trends consolidating AI platforms for faster biomarker and therapeutic discovery.[1][2] Market forces like exploding patient/genomic datasets, regulatory pushes for efficient trials, and unmet needs in CNS/rare diseases favor its approach, influencing the ecosystem by enabling partners to repurpose drugs and stratify patients while Renovaro expands it into oncology.[1][4]

Quick Take & Future Outlook

Post-acquisition by Renovaro in February 2025, BioSymetrics' platform will supercharge AI-driven target validation across epilepsy, neurology, and cancer, with Elion and Phenograph accelerating diagnostics and small-molecule hits.[1] Trends like multimodal AI (phenomics + genomics + in vivo), regulatory fast-tracks for rare diseases, and biomarker synergies will propel its pipeline, potentially yielding first-in-class therapies from programs like KCC2.[4] Its influence may evolve from standalone discovery to core engine in Renovaro's precision medicine empire, redefining how data translates to patient impact in an era of complex biology.[1][4] This phenomics pioneer, born to conquer trial failures, now scales through strategic fusion.